BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29420353)

  • 1. Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.
    Czeczok TW; Stashek KM; Maxwell JE; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):94-100. PubMed ID: 29420353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
    Bellizzi AM
    Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
    Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
    J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clusterin expression in gastrointestinal neuroendocrine tumours is highly correlated with location and is helpful in determining the origin of liver metastases.
    Mourra N; Scriva A; Mansiaux Y; Gozlan S; Bennis M; Balaton A
    Histopathology; 2014 Nov; 65(5):642-50. PubMed ID: 24807631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitx2 is a useful marker of midgut-derived neuroendocrine tumours - an immunohistochemical study of 224 cases.
    Soukup J; Manethova M; Faistova H; Krbal L; Vitovcova B; Hornychova H; Drugda J; Cesak T; Netuka D; Gabalec F; Ryska A
    Histopathology; 2022 Dec; 81(6):799-807. PubMed ID: 36089904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
    Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
    Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence?
    Helpap B; Köllermann J
    Virchows Arch; 2001 Jan; 438(1):86-91. PubMed ID: 11213840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
    Yang Z; Klimstra DS; Hruban RH; Tang LH
    Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.
    Rindi G; Mete O; Uccella S; Basturk O; La Rosa S; Brosens LAA; Ezzat S; de Herder WW; Klimstra DS; Papotti M; Asa SL
    Endocr Pathol; 2022 Mar; 33(1):115-154. PubMed ID: 35294740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four cases.
    Venable ER; Kerr SE; Lopes MBS; Jones KA; Bellizzi AM; Mounajjed T; Raghunathan A; Hamidi O; Halfdanarson TR; Ryder M; Graham RP
    Diagn Pathol; 2020 Jul; 15(1):81. PubMed ID: 32622369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntaxin 1: A Novel Robust Immunophenotypic Marker of Neuroendocrine Tumors.
    Kővári B; Turkevi-Nagy S; Báthori Á; Fekete Z; Krenács L
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Non-coding RNAs in Pulmonary Neuroendocrine Neoplasms.
    Narayanan D; Mandal R; Hardin H; Chanana V; Schwalbe M; Rosenbaum J; Buehler D; Lloyd RV
    Endocr Pathol; 2020 Sep; 31(3):254-263. PubMed ID: 32388776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CD133 in neuroendocrine neoplasms of the digestive tract: a detailed immunohistochemical analysis.
    Mia-Jan K; Munkhdelger J; Lee MR; Ji SY; Kang TY; Choi E; Cho MY
    Tohoku J Exp Med; 2013 Apr; 229(4):301-9. PubMed ID: 23615455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucin phenotype expression of gastric neuroendocrine neoplasms: analysis of histopathology and carcinogenesis.
    Domori K; Nishikura K; Ajioka Y; Aoyagi Y
    Gastric Cancer; 2014 Apr; 17(2):263-72. PubMed ID: 23828549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas.
    Yu S; Hornick JL; Gonzalez RS
    Virchows Arch; 2021 Sep; 479(3):481-491. PubMed ID: 33733343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
    Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine neoplasms of the appendix, colon and rectum.
    Volante M; Grillo F; Massa F; Maletta F; Mastracci L; Campora M; Ferro J; Vanoli A; Papotti M
    Pathologica; 2021 Feb; 113(1):19-27. PubMed ID: 33686307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CytoLyt fixation impedes insulinoma-associated protein 1 (INSM1) immunoreactivity compared to formalin fixation.
    Garlin-Politis M; Upadhyay Baskota S; Picon S; Collins N; Virk RK; Cimic A; Yousefi E; Gonzalez A
    J Am Soc Cytopathol; 2024; 13(3):213-218. PubMed ID: 38575468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.